Orencia (abatacept) is CHMP recommended to treat active psoriatic arthritis (PsA).-BMS.

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Orencia (abatacept) from BMS. The marketing authorisation holder for this medicinal product is Bristol-Myers Squibb Pharma The CHMP adopted a new indication as follows: “Orencia, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required.”